Glaukos Wins FDA Nod for Glaucoma Treatment Implant

In case you missed it, Glaukos, a prominent player in the Microinvasive Glaucoma Surgery (MIGS) space completed a 15-year regulatory journey.

The San Clemente, CA-based company won a nod from FDA for the iDose travoprost intracameral (TR) implant, indicated for use in patients with primary open-angle glaucoma (OAG) or ocular hypertension.